Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'irinotecan' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 394 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Tsai, TH
      Analytical approaches for traditional Chinese medicines exhibiting antineoplastic activity

      JOURNAL OF CHROMATOGRAPHY B
    2. Oguma, T
      Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods

      JOURNAL OF CHROMATOGRAPHY B
    3. Palumbo, M; Sissi, C; Gatto, B; Moro, S; Zagotto, G
      Quantitation of camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    4. Zufia, L; Aldaz, A; Giraldez, J
      Separation methods for camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    5. Jung, LL; Zamboni, WC
      Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

      DRUG RESISTANCE UPDATES
    6. Mathijssen, RHJ; van Alphen, RJ; Verweij, J; Loos, WJ; Nooter, K; Stoter, G; Sparreboom, A
      Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)

      CLINICAL CANCER RESEARCH
    7. Takimoto, CH
      Why drugs fail: Of mice and men revisited

      CLINICAL CANCER RESEARCH
    8. Kirstein, MN; Houghton, PJ; Cheshire, PJ; Richmond, LB; Smith, AK; Hanna, SK; Stewart, CF
      Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts

      CLINICAL CANCER RESEARCH
    9. Minami, H; Fujii, H; Igarashi, T; Itoh, K; Tamanoi, K; Oguma, T; Sasaki, Y
      Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks

      CLINICAL CANCER RESEARCH
    10. Senter, PD; Beam, KS; Mixan, B; Wahl, AF
      Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug

      BIOCONJUGATE CHEMISTRY
    11. Takagi, T; Saotome, T
      Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    12. Launois, R; Portafax, C; Le Lay, K; Megnigbeto, A; Perrocheau, G
      Internet pharmaco-economic studies in metastatic colorectal cancer

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    13. Platzer, P; Thalhammer, T; Reznicek, G; Hamilton, G; Zhang, RW; Jager, W
      Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver

      INTERNATIONAL JOURNAL OF ONCOLOGY
    14. Maindrault-Goebel, F; de Gramont, A; Louvet, C; Andre, T; Carola, E; Mabro, M; Artru, P; Gilles, V; Lotz, JP; Izrael, V; Krulik, M
      High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

      EUROPEAN JOURNAL OF CANCER
    15. Cunningham, D; James, RD
      Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer

      EUROPEAN JOURNAL OF CANCER
    16. Alonso, V; Escudero, P; Zorrilla, M; Isla, MD; Herrero, A; Mayordomo, JI; Martinez-Trufero, J; Saenz, A; Tres, A; Anton, A
      Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer

      EUROPEAN JOURNAL OF CANCER
    17. Ohe, Y; Yamamoto, S; Suzuki, K; Hojo, F; Kakinuma, R; Matsumoto, T; Ohmatsu, H; Nishiwaki, Y
      Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer

      EUROPEAN JOURNAL OF CANCER
    18. Guichard, S; Arnould, S; Hennebelle, I; Bugat, R; Canal, P
      Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo

      ANTI-CANCER DRUGS
    19. Ong, SYK; Clarke, SJ; Bishop, J; Dodds, HM; Rivory, LP
      Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction

      ANTI-CANCER DRUGS
    20. Yamamoto, W; Verweij, J; de Bruijn, P; de Jonge, MJA; Takano, H; Nishiyama, M; Kurihara, M; Sparreboom, A
      Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

      ANTI-CANCER DRUGS
    21. Kehrer, DFS; Soepenberg, O; Loos, WJ; Verweij, J; Sparreboom, A
      Modulation of camptothecin analogs in the treatment of cancer: a review

      ANTI-CANCER DRUGS
    22. Demarquay, D; Huchet, M; Coulomb, H; Lesueur-Ginot, L; Lavergne, O; Kasprzyk, PG; Bailly, C; Camara, J; Bigg, DCH
      The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison

      ANTI-CANCER DRUGS
    23. Green, MR
      The current status of docetaxel for advanced non-small cell lung cancer

      ANTI-CANCER DRUGS
    24. Barbounis, V; Koumakis, G; Vassilomanolakis, M; Demiri, M; Efremidis, AP
      Control of irinotecan-induced diarrhea by octreotide after loperamide failure

      SUPPORTIVE CARE IN CANCER
    25. Vermorken, JB; Zanetta, G; Oliveira, CFD; van der Burg, MEL; Lacave, AJ; Teodorovic, I; Boes, GH; Colombo, N
      Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma ofthe uterine cervix: An EORTC Gynecological Cancer Cooperative Group study

      ANNALS OF ONCOLOGY
    26. Alberts, SR; Erlichman, C; Sloan, J; Okuno, SH; Burch, PA; Rubin, J; Pitot, HC; Goldberg, RM; Adjei, AA; Atherton, PJ; Kaufmann, SH
      Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks

      ANNALS OF ONCOLOGY
    27. Scheithauer, W; Kornek, GV; Schuell, B; Ulrich-Pur, H; Penz, M; Raderer, M; Lang, F; Schneeweiss, B; Lenauer, A; Depisch, D
      Second-line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy

      ANNALS OF ONCOLOGY
    28. Sanz-Altamira, PM; O'Reilly, E; Stuart, KE; Raeburn, L; Steger, C; Kemeny, NE; Saltz, LB
      A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma

      ANNALS OF ONCOLOGY
    29. Volk, J; Reinke, F; van Kuilenburg, ABP; van Gennip, AH; Schlichting, C; Ganser, A; Schoffski, P
      Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer

      ANNALS OF ONCOLOGY
    30. Grumett, SA; Archer, VR; Midgley, R; Mulholland, P; Nicum, S; Blewitt, L; Kerr, DJ
      The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy

      ANNALS OF ONCOLOGY
    31. Bonetti, A; Zaninelli, M; Leone, R; Franceschi, T; Fraccon, AP; Pasini, F; Sabbioni, R; Cetto, GL; Sich, D; Brienza, S; Howell, SB
      Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma

      ANNALS OF ONCOLOGY
    32. Huisman, C; Postmus, PE; Giaccone, G; Smit, EF
      A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients

      ANNALS OF ONCOLOGY
    33. Blanke, CD; Haller, DG; Benson, AB; Rothenberg, ML; Berlin, J; Mori, M; Hsieh, YC; Miller, LL
      A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma

      ANNALS OF ONCOLOGY
    34. Rothenberg, ML; Kuhn, JG; Schaaf, LJ; Rodriguez, GI; Eckhardt, SG; Villalona-Calero, MA; Rinaldi, DA; Hammond, LA; Hodges, S; Sharma, A; Elfring, GL; Petit, RG; Locker, PK; Miller, LL; von Hoff, DD
      Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks

      ANNALS OF ONCOLOGY
    35. Oguma, T; Yamada, M; Konno, T; Inukai, K; Nakaoka, M
      High-performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (Exatecan), in mouse plasma

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    36. Sakai, C; Iuchi, T; Ishii, A; Kumagai, K; Takagi, T
      Bacillus cereus brain abscesses occurring in a severely neutropenic patient: Successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage

      INTERNAL MEDICINE
    37. Shimizu, M; Tamura, T; Yamada, Y; Akiyama, Y; Saijo, N; Nishio, K
      CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNAin mouse liver

      JAPANESE JOURNAL OF CANCER RESEARCH
    38. Haller, DG
      Update on chemotherapy for advanced colorectal cancer

      ONCOLOGY-NEW YORK
    39. Rich, TA; Kirichenko, AV
      Camptothecin schedule and timing of administration with irradiation

      ONCOLOGY-NEW YORK
    40. Beretta, GD; Pessi, MA; Poletti, P; Mosconi, S; Labianca, R
      New drugs and combinations in the palliative treatment of colon and rectalcancer

      EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    41. Hoff, PM; Ansari, R; Batist, G; Cox, J; Kocha, W; Kuperminc, M; Maroun, J; Walde, D; Weaver, C; Harrison, E; Burger, HU; Osterwalder, B; Wang, AO; Wong, R
      Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study

      JOURNAL OF CLINICAL ONCOLOGY
    42. Taamma, A; Misset, JL; Riofrio, M; Guzman, C; Brain, E; Lazaro, LL; Rosing, H; Jimeno, JM; Cvitkovic, E
      Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    43. Vanhoefer, U; Harstrick, A; Achterrath, W; Cao, SS; Seeber, S; Rustum, YM
      Irinotecan in the treatment of colorectal cancer: Clinical overview

      JOURNAL OF CLINICAL ONCOLOGY
    44. Van Cutsem, E; Twelves, C; Cassidy, J; Allman, D; Bajetta, E; Boyer, M; Bugat, R; Findlay, M; Frings, S; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Vieitez, JM; Weitzel, C; Harper, P
      Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study

      JOURNAL OF CLINICAL ONCOLOGY
    45. de Jongh, FE; Verweij, J; Loos, WJ; de Wit, R; de Jonge, MJA; Planting, AST; Nooter, K; Stoter, G; Sparreboom, A
      Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

      JOURNAL OF CLINICAL ONCOLOGY
    46. Arimori, K; Kuroki, N; Kumamoto, A; Tanoue, N; Nakano, M; Kumazawa, E; Tohgo, A; Kikuchi, M
      Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents

      PHARMACEUTICAL RESEARCH
    47. Nolte, W; Ramadori, G
      New aspects in the palliative treatment of metastatic colorectal carcinoma

      MEDIZINISCHE KLINIK
    48. Reimer, P; Ruckle-Lanz, H
      New therapeutic options in the chemotherapy of advanced colorectal cancer

      MEDIZINISCHE KLINIK
    49. Louvet, C
      New chemotherapies for colorectal cancer treatment

      GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    50. Azevedo, P; Verschraegen, CF; Kavanagh, JJ; Kudelka, AP; Freedman, RS; Lu, K; Deavers, MT
      Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report

      EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
    51. Honecker, F; Wedding, U; Kolb, G; Bokemeyer, C
      Chemotherapy in colorectal cancer - Which therapy is justified in elderly patients?

      ONKOLOGIE
    52. Shigeoka, Y; Itoh, K; Igarashi, T; Ishizawa, K; Saeki, T; Fujii, H; Minami, H; Imoto, S; Sasaki, Y
      Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    53. Crane, CH; Janjan, NA; Abbruzzese, JL; Curley, S; Vauthey, JN; Sawaf, HB; Dubrow, R; Allen, P; Ellis, LM; Hoff, P; Wolff, RA; Lenzi, R; Brown, TD; Lynch, P; Cleary, K; Rich, TA; Skibber, J
      Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    54. Sloan, JA; Atherton, P; Reid, J; Pilot, HC; Erlichman, C; Schaaf, L
      Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    55. Cavazos, CM; Keir, ST; Yoshinari, T; Bigner, DD; Friedman, HS
      Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    56. Takeda, K; Negoro, S; Takifuji, N; Nitta, T; Yoshimura, N; Terakawa, K; Fukuoka, M
      Dose escalation study of irinotecan combined with carboplatin for advancednon-small-cell lung cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    57. Keir, ST; Hausheer, F; Lawless, AA; Bigner, DD; Friedman, HS
      Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    58. Sato, A; Kurihara, M; Matsukawa, M; Shimada, K; Yamazaki, T; Nakamachi, M; Koda, T
      Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    59. Guemei, AA; Cottrell, J; Band, R; Hehman, H; Prudhomme, M; Pavlov, MV; Grem, JL; Ismail, AS; Bowen, D; Taylor, RE; Takimoto, CH
      Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    60. Thompson, J; Guichard, SM; Cheshire, PJ; Richmond, LB; Poquette, CA; Ragsdale, ST; Webber, B; Lorsbach, R; Danks, MK; Houghton, PJ
      Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    61. Kobayashi, K; Ceryak, S; Matsuzaki, Y; Kudoh, S; Bouscarel, B
      Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

      BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
    62. Grifalchi, F; Padovani, A; Romeo, F; Trinca, C; Moscetti, L; Cortesi, E
      Response of metastatic epidermoid anal cancer to single agent irinotecan: A case report

      TUMORI
    63. Lokich, J
      Phase I clinical trial of weekly combined topotecan and irinotecan

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    64. Gil-Delgado, MA; Antoine, EC; Guinet, F; Bassot, V; Grapin, JP; Benhammonda, A; Adam, R; Castaing, D; Bismuth, H; Khayat, D
      Phase I-II study of irinotecan in combination with mitomycin C in patientswith advanced gastrointestinal cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    65. Shields, AF; Lange, M; Zalupski, MM
      Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    66. Gil-Delgado, MA; Guinet, F; Castaing, D; Adam, R; Coeffic, D; Durrani, AKS; Bismuth, H; Khayat, D
      Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    67. Topcu, Z
      DNA topoisomerases as targets for anticancer drugs

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    68. Hanioka, N; Jinno, H; Nishimura, T; Ando, M; Ozawa, S; Sawada, J
      High-performance liquid chromatographic assay for glucuronidation activityof 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes

      BIOMEDICAL CHROMATOGRAPHY
    69. Wang, XH; Fujimoto, T; Zhang, B; Mai, M
      Streptococcal preparation OK-432 enhances the antitumor activity of CPT-11by increasing Th1-cytokine production in mice

      ANTICANCER RESEARCH
    70. Vokes, EE; Gordon, GS; Rudin, CM; Mauer, AM; Watson, S; Krauss, S; Arrieta, R; Golomb, HM; Hoffman, PC
      A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

      INVESTIGATIONAL NEW DRUGS
    71. Pro, B; Lozano, R; Ajani, JA
      Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea

      INVESTIGATIONAL NEW DRUGS
    72. Miya, T; Goya, T; Fujii, H; Ohtsu, T; Itoh, K; Igarashi, T; Minami, H; Sasaki, Y
      Factors affecting the pharmacokinetics of CPT-11: The body mass index, ageand sex are independent predictors of pharmacokinetic parameters of CPT-11

      INVESTIGATIONAL NEW DRUGS
    73. Turker, L
      A theoretical study on camptothecin-AM1 treatment

      JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
    74. Grivicich, I; Mans, DRA; Peters, GJ; Schwartsmann, G
      Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer

      BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
    75. Prados, M
      Temozolomide in combination with other cytotoxic agents

      SEMINARS IN ONCOLOGY
    76. O'Connell, MJ
      North Central Cancer Treatment Group-Mayo Clinic trials in colon cancer

      SEMINARS IN ONCOLOGY
    77. Sai, K; Kaniwa, N; Ozawa, S; Sawada, JI
      A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4

      DRUG METABOLISM AND DISPOSITION
    78. Hanioka, N; Ozawa, S; Jinno, H; Ando, M; Saito, Y; Sawada, J
      Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin

      XENOBIOTICA
    79. Comella, P; Biglietto, M; Casaretti, R; De Luica, L; Avallone, A; Maiorino, L; Di Lullo, L; De Cataldis, G; Rivellini, F; Comella, G
      Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients - A phase I/II study of the Southern Italy Cooperative Oncology Group

      ONCOLOGY
    80. Wadkins, RM; Morton, CL; Weeks, JK; Oliver, L; Wierdl, M; Danks, MK; Potter, PM
      Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases

      MOLECULAR PHARMACOLOGY
    81. Farabos, C; Haaz, MC; Gires, P; Robert, J
      Hepatic extraction, metabolism, and biliary excretion of irinotecan in theisolated perfused rat liver

      JOURNAL OF PHARMACEUTICAL SCIENCES
    82. Takeda, Y; Kobayashi, K; Akiyama, Y; Soma, T; Handa, S; Kudoh, S; Kudo, K
      Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

      INTERNATIONAL JOURNAL OF CANCER
    83. Fujita, A; Takabatake, H; Tagaki, S; Sekine, K
      Combination chemotherapy in patients with malignant pleural effusions fromnon-small cell lung cancer - Cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support

      CHEST
    84. Iyengar, RV; Pawlik, CA; Krull, EJ; Phelps, DA; Burger, RA; Harris, LC; Potter, PM; Danks, MK
      Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression

      CANCER RESEARCH
    85. Boushey, RP; Yusta, B; Drucker, DJ
      Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor

      CANCER RESEARCH
    86. Wierdl, M; Morton, CL; Weeks, JK; Danks, MK; Harris, LC; Potter, PM
      Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase

      CANCER RESEARCH
    87. Meck, MM; Wierdl, M; Wagner, LM; Burger, RA; Guichard, SM; Krull, EJ; Harris, LC; Potter, PM; Danks, MK
      A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11

      CANCER RESEARCH
    88. Firvida, JL; Irigoyen, A; Vazquez-Estevez, S; Diz, P; Constenla, M; Casal-Rubio, J; Valladares-Ayerbes, M; Castellanos, J; Rodriguez, R; Balcells, M
      Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma

      CANCER
    89. Garufi, G; Dogliotti, L; D'Attino, RM; Tampellini, M; Aschelter, AM; Pugliese, P; Perrone, M; Nistico, C; Comis, S; Terzoli, E
      Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acidin the treatment of patients with advanced colorectal carcinoma - A phase I study

      CANCER
    90. O'Reilly, EM; Stuart, KE; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Raeburn, L; Kemeny, NE; Kelsen, DP; Saltz, LB
      A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

      CANCER CYTOPATHOLOGY
    91. O'Reilly, EM; Stuart, KE; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Raeburn, L; Kemeny, NE; Kelsen, DP; Saltz, LB
      A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

      CANCER
    92. Ducreux, N; Fizazi, K; Seitz, JF; Becouarn, Y; Armand, JP
      Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer

      BULLETIN DU CANCER
    93. Dodds, HM; Rivory, LP
      Comment on a published paper

      BRITISH JOURNAL OF PHARMACOLOGY
    94. Blandizzi, C; De Paolis, B; Colucci, R; Lazzeri, G; Baschiera, F; Del Tacca, M
      Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan

      BRITISH JOURNAL OF PHARMACOLOGY
    95. Chau, I; Webb, A; Cunningham, D; Hill, M; Waters, JS; Norman, A; Massey, A
      Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer

      BRITISH JOURNAL OF CANCER
    96. Cyjon, A; Neuman-Levin, M; Rakowsky, E; Greif, F; Belinky, A; Atar, E; Hardoff, R; Brenner, B; Sulkes, A
      Liver metastases from colorectal cancer: regional intra-arterial treatmentfollowing failure of systemic chemotherapy

      BRITISH JOURNAL OF CANCER
    97. Bensmaine, MA; Marty, M; de Gramont, A; Brienza, S; Levi, F; Ducreux, M; Francois, E; Gamelin, E; Bleiberg, H; Cvitkovic, E
      Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

      BRITISH JOURNAL OF CANCER
    98. Ueoka, H; Tanimoto, M; Kiura, K; Tabata, M; Takigawa, N; Segawa, Y; Takata, I; Eguchi, K; Okimoto, N; Harita, S; Kamei, H; Shibayama, T; Watanabe, Y; Hiraki, S; Harada, M
      Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group

      BRITISH JOURNAL OF CANCER
    99. Sobrero, A; Guglielmi, A; Cirillo, M; Recaldin, E; Frassineti, GL; Aschele, C; Ravaioli, A; Testore, P; Caroti, C; Gallo, L; Pessi, MA; Cortesi, E; Turci, D; Grossi, F; Labianca, R
      5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highlyeffective, low cost chemotherapy for advanced colorectal cancer

      BRITISH JOURNAL OF CANCER
    100. Fischel, JL; Rostagno, P; Formento, P; Dubreuil, A; Etienne, MC; Milano, G
      Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines

      BRITISH JOURNAL OF CANCER


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/21 alle ore 00:26:43